Form 4: Camp4 Therapeutics Director Granted 9,000 Stock Options

Camp4 Therapeutics Corp. Director Ravi I. Thadhani was granted 9,000 stock options with an exercise price of $1.56, vesting on the earlier of the first anniversary of the grant date or the next annual meeting of stockholders.

Summary

• Ravi I. Thadhani, a Director of Camp4 Therapeutics Corp. (CAMP), acquired 9,000 stock options.
• The transaction date for this acquisition was June 25, 2025.
• Each option has an exercise price of $1.56.
• The options vest in their entirety on the earlier of the first anniversary of the grant date or the date of the issuer's next annual meeting of stockholders, contingent on continued service to the board.
• The options expire on June 24, 2035.

Sentiment

Score: 7

Explanation: The grant of stock options to a director is a standard and generally positive corporate governance practice, aligning the director's interests with long-term shareholder value. It does not indicate any negative operational or financial news, nor does it suggest immediate significant positive news beyond routine compensation.

Positives

• The granting of stock options to a director aligns their interests with shareholders, incentivizing long-term performance and value creation.
• The options have a long expiration date of June 24, 2035, providing ample time for potential value appreciation.

Negatives

• This grant does not represent an immediate cash inflow for the company.
• There is a potential for future dilution of existing shares if these options are exercised, although this is a standard aspect of equity compensation plans.

Risks

• The vesting of the options is contingent upon Ravi I. Thadhani's continued service to the issuer's board of directors through the applicable vesting date.
• The financial benefit of these options to the director, and by extension their alignment with shareholder value, is dependent on the future market price of Camp4 Therapeutics Corp. common stock exceeding the exercise price of $1.56.

Future Outlook

The stock options are set to vest in their entirety on the earlier of the first anniversary of the grant date (June 25, 2026) or the date of the issuer's next annual meeting of stockholders, provided the director continues their service to the board.

Industry Context

The granting of stock options to directors is a common and widely accepted practice in the biotechnology and pharmaceutical industries. This method of compensation is frequently used by growth-oriented companies like Camp4 Therapeutics to attract and retain experienced board members, aligning their long-term interests with the company's strategic goals and shareholder value creation.

Comparison to Industry Standards

• The use of stock options with a vesting schedule and a defined exercise price is a standard form of equity compensation for directors across publicly traded companies, particularly prevalent in the biotech sector where long-term value creation is a key focus.
• Without specific details on the compensation packages of directors at comparable biotech companies (e.g., those in similar development stages or market capitalizations), a direct quantitative comparison of the grant size or exercise price is not feasible from this document alone. However, the mechanism itself is consistent with industry norms.

Related Party Transactions

• Grant of 9,000 stock options to Ravi I. Thadhani, a Director of Camp4 Therapeutics Corp., as part of his compensation package.

Stakeholder Impact

• Shareholders: Potential for enhanced alignment of director interests with long-term shareholder value. There is also a potential for future share dilution if the options are exercised, though this is a common aspect of equity compensation.
• Employees: No direct impact mentioned.
• Customers: No direct impact mentioned.
• Suppliers: No direct impact mentioned.
• Creditors: No direct impact mentioned.

Next Steps

• The stock options will vest on the earlier of June 25, 2026 (first anniversary of grant date) or the date of Camp4 Therapeutics Corp.'s next annual meeting of stockholders.
• Ravi I. Thadhani must continue his service to the issuer's board of directors for the options to vest.

Key Dates

Keywords

Camp4 Therapeutics, CAMP, Stock Options, Director Compensation, SEC Form 4, Equity Grant, Insider Transaction